eznews.in
A recent study published in *BMJ Medicine* highlights the significance of both the timing and duration of eating windows in the context of time-restricted eating (TRE), a popular form of intermittent fasting. Researchers analyzed data from over 2,200 participants across 41 randomized controlled trials, concluding that earlier eating windows yield greater metabolic health benefits compared to late-day eating. The study found that late eating, particularly when combined with longer eating windows, was the least effective for metabolic advantages, potentially conflicting with circadian rhythms. Ling-Wei Chen, the study's senior author, emphasized the need for practical dietary strategies amid rising metabolic diseases, noting that aligning food intake with the body's natural rhythms can enhance health outcomes. Experts suggest individuals should consider their natural hunger cues and choose a consistent eating window that fits their lifestyle, advocating for flexibility and quality in food choices to support metabolic regulation. 
Published: Feb 13 2026, 6 pmeznews.inA recent study published in the journal *Neurology* suggests that engaging in lifelong learning activities, such as reading and learning new languages, may significantly reduce the risk of developing Alzheimer’s disease. With around 32 million people worldwide currently living with the condition, researchers observed nearly 2,000 participants, averaging 80 years old, over an average of eight years. Those who actively pursued cognitive enrichment throughout their lives were found to develop Alzheimer’s five years later and mild cognitive impairment seven years later than those with less engagement. Specifically, individuals with higher lifetime enrichment scores exhibited a 38% lower risk of Alzheimer’s and a 36% lower risk of cognitive impairment. Experts emphasize the importance of sustained cognitive engagement from an early age, highlighting that even modest lifestyle changes can greatly enhance quality of life and delay the onset of cognitive decline. Future research is needed to explore causal relationships and the effectiveness of different enrichment components across diverse populations.
Published: Feb 13 2026, 5 pmeznews.inA new study suggests that computer-based cognitive speed training may significantly reduce the risk of dementia in older adults, potentially delaying its onset by up to 20 years. Conducted by researchers at Johns Hopkins, the study involved approximately 2,800 participants, averaging 74 years old, who were divided into groups to undergo different forms of cognitive training, including speed, memory, and reasoning exercises. Participants who completed speed training and subsequent booster sessions demonstrated a 25% reduction in dementia diagnoses over two decades compared to a control group. Experts emphasize that the findings highlight the importance of targeted, active cognitive interventions rather than passive exposure. While the study does not claim to prevent dementia outright, it underscores the potential for cognitive training to delay its onset, offering hope for improved quality of life for aging individuals. Future research is needed to explore the optimal timing and personalization of such interventions.
Published: Feb 12 2026, 11 pmeznews.inRecent updates from the UK regarding GLP-1 receptor agonists, such as Wegovy, Ozempic, and Mounjaro, have highlighted a small but notable risk of acute pancreatitis associated with these weight-loss and diabetes medications. While these injections have gained popularity, with 1.6 million adults in England, Wales, and Scotland using them between 2024 and 2025, reports of pancreatitis have prompted health authorities to revise guidelines. Experts emphasize that while pancreatitis is a recognized but rare side effect, affecting about one in 100 patients, it should not cause undue alarm. Patients are urged to be vigilant for symptoms such as severe abdominal pain, nausea, and vomiting, and to seek immediate medical attention if they occur. The guidance aims to ensure patient safety while balancing the benefits of these medications, which are considered to have a favorable safety profile for most users without pre-existing pancreatic conditions.
Published: Feb 12 2026, 2 pmeznews.inA new study published in *Science Translational Medicine* suggests that levetiracetam, a long-established anti-seizure medication, may help slow the progression of Alzheimer’s disease. Researchers conducted experiments using animal models, human neurons, and brains from individuals at high risk of developing the disease, finding that the drug reduced the accumulation of amyloid-beta proteins, which are linked to Alzheimer’s. The study indicates that levetiracetam may prevent misfolding of amyloid precursor protein (APP) by slowing its recycling at the neuronal cell surface, thereby reducing toxic protein formation. Although the findings are promising, the authors caution that more research is needed before repurposing the drug for Alzheimer’s patients, particularly since it may need to be administered early to be effective. Current data also suggest that levetiracetam may slow cognitive decline in Alzheimer’s patients, but further clinical validation is necessary to establish optimal treatment protocols.
Published: Feb 12 2026, 3 ameznews.inA recent study published in The British Medical Journal suggests that testing menstrual blood for Human Papillomavirus (HPV) could provide a less invasive alternative to traditional cervical screenings. Conducted in Hubei Province, China, the research involved over 3,000 women aged 20 to 54, comparing the accuracy of menstrual blood samples with clinician-collected cervical samples. Results indicated that menstrual blood testing had a sensitivity of 94.7%, slightly outperforming the 92.1% sensitivity of cervical samples, while specificity was marginally lower. This method could reduce barriers to screening, particularly for individuals uncomfortable with traditional procedures due to pain, stigma, or privacy concerns. Experts advocate for further studies to validate these findings across diverse populations, emphasizing that while promising, this approach may not suit everyone, particularly those who do not menstruate regularly. If successful, menstrual blood testing could enhance cervical cancer screening uptake and accessibility.
Published: Feb 11 2026, 5 pmeznews.inA comprehensive meta-analysis published in *The Lancet* has found that statins, widely prescribed to lower cholesterol and reduce cardiovascular risks, are not linked to most of the side effects listed by manufacturers, including memory loss, dementia, and depression. The study, which analyzed data from 19 randomized controlled trials involving over 123,000 participants, revealed that only four out of 66 side effects showed a higher incidence in statin users compared to those on placebo. While there was a minor increase in liver blood test abnormalities, this did not correlate with a rise in liver disease risk. Lead author Christina Reith from Oxford University emphasized the need for revised health information regarding statins, as many patients have been deterred from taking them due to unfounded fears of side effects. The findings aim to reassure patients about the benefits of statins in preventing heart attacks and strokes, while encouraging shared decision-making between patients and healthcare providers.
Published: Feb 11 2026, 12 ameznews.inA recent study published in *Gastroenterology* has highlighted the potential benefits of time-restricted eating for individuals with Crohn’s disease, a chronic inflammatory bowel condition. Conducted in Canada, the randomized controlled trial involved participants who followed an eight-hour eating window, resulting in significant weight loss, improved inflammation, and reduced disease activity, including a 40% decrease in stool frequency and halved abdominal discomfort. The intervention group also exhibited enhanced gut health, with increased microbial diversity and beneficial short-chain fatty acid-producing microbes. While the study's small sample size and short duration limit its generalizability, experts suggest that the findings offer promising insights into non-pharmacological strategies for managing Crohn’s disease. Researchers advocate for further long-term studies to explore the implications of intermittent fasting on remission and overall health in patients with Crohn’s, emphasizing the importance of consulting healthcare providers before making dietary changes.
Published: Feb 11 2026, 1 ameznews.inA recent study published in *JAMA* suggests that moderate consumption of caffeinated coffee or tea may significantly reduce the risk of dementia, slow cognitive decline, and preserve cognitive function. Analyzing health data from over 131,000 participants in the Nurses’ Health Study and Health Professionals Follow-Up Study, researchers found that those who drank two to three cups of coffee daily had an 18% lower risk of developing dementia compared to non-consumers. The findings align with previous research indicating that caffeine, along with other nutrients like flavonoids and antioxidants, may benefit brain health. Experts note that while these results are promising, they highlight an association rather than causation and stress the importance of a holistic approach to cognitive health, including diet, physical activity, and social engagement. As such, individuals should consider a balanced dietary pattern rather than relying solely on caffeinated beverages for cognitive protection.
Published: Feb 10 2026, 10 pmeznews.inNovo Nordisk's latest drug, CagriSema, has shown promising results in a 68-week clinical trial, outperforming semaglutide (Wegovy) in weight loss and blood sugar control. Participants receiving weekly injections of CagriSema experienced an average weight loss of 14.2% and a reduction in HbA1C scores by 1.91%, compared to 10.2% weight loss and 1.76% HbA1C reduction for those on semaglutide alone. CagriSema is a fixed-dose combination of semaglutide and cagrilintide, an amylin receptor agonist, which together enhance appetite control and glucose regulation. The trial involved 2,728 adults with type 2 diabetes inadequately managed by metformin. Novo Nordisk plans to submit a New Drug Application to the FDA for CagriSema by December 2025. Experts caution that while results are promising, further independent trials are necessary to fully understand the drug's effectiveness and side effects.
Published: Feb 10 2026, 12 amFor the fastest, latest, not so wokest news, 'experts say' you need to visit Eznews
India
World
Economy
Science
Health
Showbiz
Contact